FOR AGENT/BROKER USE ONLY. DO NOT DISTRIBUTE.

EncircleRx: Cardiodiabesity: updated cost share offering

With EncircleRx Highly Automated Prior Authorization (PA) , clients have more options for managing weight loss drug utilization management.

Evernorth EncircleRx^SM: Cardiodiabesity, part of our GLP-1 management suite of solutions, gives plans more optionality when managing cardiodiabesity, the interconnected conditions of obesity, diabetes and cardiovascular disease.

EncircleRx offers clients a pathway to better support the overall health and wellness of plan members in a way that suits their needs and budget and is sustainable.

To address a growing trend of direct-to-consumer GLP-1 purchases, EncircleRx offers a highly automated utilization option for weight loss. This option focuses on the lowest plan net cost per prescription and keeps member copays at no more than $200 for Zepbound® and Wegovy®—lower than current direct-to-consumer offerings on the market.

What you need to know:

Access to direct-to-consumer-like price points with highly automated utilization management

Clients have the option to charge higher patient copay (up to $200 per 30-day Rx) with Zepbound® and Wegovy®

Lifestyle modification program enrollment is optional

GLP-1 anti-fraud protection provided

Enrollment in EnReachRx^SM is required

No financial guarantees available

EncircleRx: Cardiodiabesity: updated cost share offering

Evernorth EncircleRxSM: Cardiodiabesity, part of our GLP-1 management suite of solutions, gives plans more optionality when managing cardiodiabesity, the interconnected conditions of obesity, diabetes and cardiovascular disease.

What you need to know:

Questions? Contact our team.

Evernorth EncircleRx^SM: Cardiodiabesity, part of our GLP-1 management suite of solutions, gives plans more optionality when managing cardiodiabesity, the interconnected conditions of obesity, diabetes and cardiovascular disease.